Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss ... Zepbound sales reached $1.9 billion in the fourth quarter of 2024, compared with $176 million during the same period in 2023 — when it ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Katherine Wolkoff for The New York Times Supported by By Lisa Miller Lisa Miller interviewed more than two dozen people about the effects weight-loss ... took her first dose of Zepbound on March ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Zepbound is ... effectiveness. A 6-month study of Rybelsus found an average drop of 1 to 1.3% A1C in adults with a starting A1C of 8.3%. While Rybelsus is not a weight loss medication, the ...